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Abstract
Purpose We prospectively evaluated whether a strategy
using point spread function (PSF) reconstruction for both
diagnostic and quantitative analysis in non-small cell lung
cancer (NSCLC) patients meets the European Association of
Nuclear Medicine (EANM) guidelines for harmonization of
quantitative values.
Methods The NEMA NU-2 phantom was used to determine
the optimal filter to apply to PSF-reconstructed images in
order to obtain recovery coefficients (RCs) fulfilling the
EANM guidelines for tumour positron emission tomography
(PET) imaging (PSFEANM). PET data of 52 consecutive
NSCLC patients were reconstructed with unfiltered PSF re-
construction (PSFallpass), PSFEANM and with a conventional
ordered subset expectation maximization (OSEM) algorithm
known to meet EANM guidelines. To mimic a situation in
which a patient would undergo pre- and post-therapy PET
scans on different generation PET systems, standardized up-
take values (SUVs) for OSEM reconstruction were compared
to SUVs for PSFEANM and PSFallpass reconstruction.
Results Overall, in 195 lesions, Bland-Altman analysis dem-
onstrated that the mean ratio between PSFEANM and OSEM
data was 1.03 [95 % confidence interval (CI) 0.94–1.12] and
1.02 (95 % CI 0.90–1.14) for SUVmax and SUVmean, respec-
tively. No difference was noticed when analysing lesions
based on their size and location or on patient body habitus
and image noise. Ten patients (84 lesions) underwent two
PET scans for response monitoring. Using the European
Organization for Research and Treatment of Cancer
(EORTC) criteria, there was an almost perfect agreement
between OSEMPET1/OSEMPET2 (current standard) and
OSEMPET1/PSFEANM-PET2 or PSFEANM-PET1/OSEMPET2
with kappa values of 0.95 (95 % CI 0.91–1.00) and 0.99
(95 % CI 0.96–1.00), respectively. The use of PSFallpass
either for pre- or post-treatment (i.e. OSEMPET1/PSFallpass-
PET2 or PSFallpass-PET1/OSEMPET2) showed considerably less
agreement with kappa values of 0.75 (95 % CI 0.67–0.83)
and 0.86 (95 % CI 0.78–0.94), respectively.
Conclusion Protocol-optimized images and compliance
with EANM guidelines allowed for a reliable pre- and
post-therapy evaluation when using different generation
PET systems. These data obtained in NSCLC patients could
be extrapolated to other solid tumours.
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Introduction
Over the last 20 years, 18F-fluorodeoxyglucose (FDG) posi-
tron emission tomography (PET) has played an increasing role
in the management of non-small cell lung cancer (NSCLC)
patients for staging [1] and restaging [2, 3]. More recently,
18F-FDG PET has been used for response evaluation of che-
motherapy and molecularly targeted therapies [4–6]. The
standardized uptake value (SUV) is the most frequently used
quantitative parameter in oncology [7]. When using SUVas a
diagnostic [8, 9] or prognostic [10, 11] tool (i.e. single mea-
surement) or for therapy monitoring (i.e. longitudinal studies)
in multicentre trials or in sites equipped with multiple scan-
ners, one needs to minimize the variability in semi-
quantitative measurements by harmonizing both patient prep-
aration in the PET unit and acquisition and reconstruction
parameters [12–14].
The European Association of Nuclear Medicine (EANM)
and the Society of Nuclear Medicine (SNM) have published
guidelines [15, 16] regarding patient preparation, data acquisi-
tion, reconstruction parameters and definition of volume of
interest (VOI) in or around the tumours. With regard to recon-
struction parameters, the EANM guidelines, in line with the
Netherlands protocol for standardization and quantification
of 18F-FDG PET studies in multicentre trials [17], provide
recommendations based on an expected spatial resolution of
the PET system equal to 7 mm. These recommendations
include the use of the NEMA NU-2 phantom to check that
activity concentration recoveries are concordant with those
expected. Regarding quantitative analysis, SUVmax is current-
ly the most frequently used quantitative parameter in onco-
logical studies [18] despite being a suboptimal parameter due
to noise-induced bias [19]. Therefore the EANM guidelines
focus on getting comparable SUVs when using SUVmax in
multicentre studies.
Hardware and software evolutions can lead to important
device-dependent and reconstruction-dependent variations in
quantitative values [20–22]. For instance, point spread function
(PSF) reconstruction, which improves spatial resolution
throughout the entire field of view, has recently become com-
mercially available in clinical PET/CT systems. Our group has
shown that, by improving activity recovery, especially for non-
enlarged nodes, PSF reconstruction significantly improves the
diagnostic performance of 18F-FDG PET for nodal staging in
NSCLC [23]. On average, PSF reconstruction increases
SUVmax and SUVmean by 48 and 28 %, respectively. As a
result, recovery coefficient (RC) values obtained with PSF
reconstruction are much higher than EANM’s expected activity
concentration recoveries as shown recently by Boellaard [24].
There is therefore a need for standardization of reconstruc-
tion protocols, keeping in mind that centres running PET
systems with advanced reconstruction algorithms that partic-
ipate in multicentre trials often wish to use their PET system
with parameters chosen in order to achieve optimal lesion
detection. A solution to optimize PET image quality for diag-
nostic purposes and at the same time to be able to use quan-
titative values within the framework of multicentre trials is the
use of an additional filtering step [25] or to generate two sets
of images: one to provide optimal diagnostic quality and a
second one to meet quantitative harmonizing standards [24],
with NEMA NU-2 phantom-based filtering chosen so that
activity concentration recoveries are as close as possible to
those recommended by EANM guidelines.
We aimed at prospectively evaluating such a strategy in
NSCLC patients imaged on a PET/CT system equipped with
PSF reconstruction. For that purpose, in order to mimic a
situation in which a patient would undergo pre- and post-
treatment scans on different generation PET systems, the
same PET raw data were reconstructed with an ordered
subset expectation maximization (OSEM) algorithm known
to produce activity concentration recoveries meeting EANM
requirements, PSF reconstruction for optimal tumour detec-
tion and PSF reconstruction with a filter optimized to fulfil
EANM requirements. In addition, the potential impact of
several confounding factors [tumour size, location and type
as well as patient body mass index (BMI) and image noise]
on the accuracy of our method was studied.
Materials and methods
Patient population
During 6 months, 52 patients referred to our institution for
staging or restaging of a NSCLC were included in this study.
The studywas approved by the local Ethics Committee (ref A12-
D24-VOL13, Comité de protection des personnes Nord Ouest
III) waiving signed informed consent. Among these patients, ten
underwent two PET examinations for the purpose of therapy
monitoring. Patient demographics are described in Table 1.
Calibration and cross-calibration of the PET system
The calibration of the PET system was performed daily with a
68Ge cylinder with a known radioactive concentration. This
cross-calibration procedure was performed twice during the
present study. A solution of 18F-FDG (70.6 and 70.5 MBq, as
assessed by the dose calibrator) was introduced into a cylin-
drical phantom with an exactly known volume and completed
with water, which resulted in a solution with an exactly known
concentration. A two-bed acquisition of the phantom was
performed and images were reconstructed with attenuation
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and scatter correction identical to patient studies. Twelve
VOIs were drawn on consecutive axial slices to determine
the average activity concentration of 18F-FDG within the
phantom. The cross-calibration factor was calculated as the
ratio of the calculated activity and the true activity. The cross-
calibration factors were found to be 0.99 and 1.04.
Phantom preparation
The phantom set is the International Electrotechnical
Commission body phantom set, which consists of a torso cavity
containing a 5-cm-diameter cylindrical insert filled with foam
pellets with an average density of 0.30 g/ml positioned in the
centre of the phantom to simulate lung tissue and six coaxial
isocentred spheres with internal diameters of 10, 13, 17, 22, 28
and 37 mm. According to the EANM guidelines, the phantom
was filled with a solution of 18F-FDG (2.0 kBq/ml) and all of
the spheres with a radioactivity concentration of 20.0 kBq/ml
resulting in a lesion to background activity ratio equal to 10.
Patient studies
The weight and height of patients on the day of the PET
examination were recorded. BMI was computed as follows
and was used to separate overweight (BMI>25 to <30 kg/m2)
and obese patients (BMI≥30 kg/m2) from low to normal
weight patients (BMI<25 kg/m2):
BMI ¼ weight kgð Þ
height 2 m2ð Þ
After a 15-min rest in a warm room, patients who had
been fasting for 6 h were injected with 18F-FDG. Mean (SD)
injected activity was 4 (0.2) MBq per kg of body weight.
The delay (SD) between tracer injection and image acquisi-
tion was 62 (4) min, thus meeting EANM guidelines [15].
PET/CT acquisition and reconstruction parameters
All PET imaging studies were performed on a Biograph TrueV
(Siemens Medical Solutions) with a 6-slice spiral CT compo-
nent. The technical and performance characteristics of the PET
component of the TrueV system can be found elsewhere [26].
CT acquisition was performed first, with the following
parameters: 60 mAs, 130 kVp, pitch 1 and 6×2 mm collima-
tion. Subsequently, the PET emission acquisition was
performed in 3-D mode. Patients were scanned from the skull
base to the mid-thighs. For low to normal weight and over-
weight to obese patients, the duration was 2min 40 s and 3min
40 s, respectively. For phantom scanning, two bed positions
were performed. The duration of each bed position was set to
2 min 40 s and 10 min, as per EANM guidelines. In addition,
phantom studies with durations of 1 min 40 s and 3 min 40 s
were performed in order to study the impact of image noise on
the accuracy of our method.
In our department, PET images are reconstructed with a PSF
reconstruction algorithm (HD; TrueX, Siemens Medical
Solutions; 3 iterations and 21 subsets) without filtering
(PSFallpass), as modelling the PSF during iterative reconstruc-
tion introduces correlations between neighbouring voxels in a
manner similar to smoothing filters and thus has been shown to
achieve maximal performance with little or no filtering [27].
For the purpose of this study, raw data were also
reconstructed with the OSEM 3-D reconstruction algorithm (4
iterations and 8 subsets) and the PSF reconstruction algorithm
(HD; TrueX, Siemens Medical Solutions; 3 iterations and 21
subsets) using aGaussian filter and an increasing kernel ranging
from 6 to 8 mm with a 0.5-mm increment. Only the PSF-
reconstructed data without filtering were used for the purpose
of diagnostic workup. The OSEM reconstruction parameters
were chosen as recommended by the manufacturer. These
parameters meet the EANM requirements regarding activity
recoveries and they were recently used by another group with
the same PET system [28]. For all reconstructions, matrix size
was 168×168, resulting in a 4.07×4.07×4.07 mm voxel size.
Scatter and attenuation corrections were applied.
PET/CT analysis
Phantom studies
Activity concentration RCs as a function of sphere (tumour)
size were measured. RCs are defined as the ratio between
measured and true activity concentration in a sphere. For that
purpose, 3-D 50 % isocontour VOIs were drawn over each
sphere for each set of reconstructed data and maximum and
mean pixel values were recorded.
Table 1 Patient demographics
Characteristic
Sex ratio (M/F) 7.7
Age (years)
Range 46–80
Mean (SD) 63.9 (7.9)
Body habitus, n (%)
BMI<25 22 (42.3)
BMI ≥ 25 to<30 22 (42.3)
BMI≥30 8 (15.4)
Histological diagnosis, n (%)
Adenocarcinoma 26 (50.0)
Squamous cell carcinoma 18 (34.6)
Undifferentiated carcinoma 4 (7.7)
Large cell carcinoma 2 (3.9)
Adenosquamous carcinoma 1 (1.9)
Neuroendocrine carcinoma 1 (1.9)
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Patient analysis
The same reader (CL) analysed all PET data sets to extract PET
quantitative values for OSEM and PSF reconstructions.
Regions of interest (ROIs) were drawn over primary tumour
lesions, mediastinal and hilar nodes considered to have patho-
logically increased uptake and metastatic lesions. ROIs were
drawn on the axial slice on which lesions displayed the highest
18F-FDG uptake, by means of a 50 % isocontour method.
The mean and maximum pixel values were extracted
from each ROI and mean and maximum SUVs were com-
puted as follows:
SUV ¼ tumour activity Bq cc=ð Þ  bodyweightðgÞ
injected dose Bqð Þ
Finally, short axis size (cm), as determined on axial CT
slices, was recorded for eachmediastinal and hilar lymph node.
For patients who underwent a post-therapeutic examina-
tion, the post-therapeutic status of each lesion was determined
by using European Organization for Research and Treatment
of Cancer (EORTC) criteria [29, 30]. SUVmax, recorded as
described above, was used. The changes in SUVmax between
the PET1 and PET2 scans were recorded for all lesions. The
percentage change in SUVmax allowed classification into the
following groups:
– Complete metabolic response (CMR): complete resolu-
tion of 18F-FDG uptake in the tumour volume (indistin-
guishable from surrounding normal tissue)
– Partial metabolic response (PMR): at least 25 % reduc-
tion in tumour uptake
– Stable metabolic disease (SMD): less than 25 % in-
crease or less than 25 % decrease in tumour 18F-FDG
SUVand no visible increase in extent of tumour uptake
– Progressive metabolic disease (PMD): greater than 25 %
increase in 18F-FDG tumour SUV within the tumour
Statistical analysis
The first step of the analysis was to determine the optimal filter
settings for PSF reconstruction to meet EANM harmonizing
standards. For that purpose, for all sets of reconstructed data,
RCs for all spheres were compared to EANM expected values
by means of the root mean square error (RMSE) method. The
kernel size that minimizes the RMSE when compared to
EANM expected values was selected as the optimal filter for
PSF reconstruction on our PET/CT system. RMSE were com-
puted with R, a freeware statistical package (http://www.r-
project.org/foundation/).
Quantitative data extracted from clinical PET/CT examina-
tions are presented as mean (standard deviation, SD). In all
Fig. 1 Recovery coefficients
for mean (a) and maximum (b)
values for OSEM 3-D
reconstruction algorithm, PSF
reconstruction algorithm
without filtering (PSFallpass) and
PSF reconstruction algorithm
with a 7-mm Gaussian filter
(PSFEANM). Corresponding
NEMA NU-2 transverse images
through the hot spheres (c).
Phantom images are scaled on
the same maximum value
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statistical tests, a two-tailed p value of less than 0.05 was
considered statistically significant. The ratios between
PSFEANM and OSEM quantitative values (SUVmean, SUVmax),
according to lesion size, location and type (heterogeneous vs
homogeneous uptake), BMI (low to normal weight vs over-
weight vs obese patients) and acquisition time per bed position
(2 min 40 s vs 3 min 40 s) were compared using the Mann–
Whitney test for unpaired samples and the Kruskal-Wallis test to
compare multiple groups. The relationship between PSFallpass
or PSFEANM and OSEM quantitative values was assessed
using a linear regression analysis and Bland-Altman plots
[31]. In the subset of ten patients that underwent two
Fig. 2 Relationship between quantitative values extracted from PSFallpass or PSFEANM and OSEM images, assessed using linear regression analysis
and Bland-Altman plots for SUVmax (a) and SUVmean (b)
Eur J Nucl Med Mol Imaging (2013) 40:985–996 989
PET/CT examinations for therapy monitoring purposes,
levels of agreement between the different types of recon-
struction were evaluated using the kappa statistic. The use
of OSEM reconstruction both for pre- and post-therapeutic
PET examination (OSEMPET1/OSEMPET2) was used as the
“current standard” to determine the post-treatment status of
each lesion. This was compared to the use of PSFEANM recon-
struction either for pre-therapeutic PET evaluation (PSFEANM-
PET1/OSEMPET2) or for post-therapeutic PET evaluation
(OSEMPET1/PSFEANM-PET2), to the use of PSFallpass reconstruc-
tion either for pre-therapeutic PET evaluation (PSFallpass-
PET1/OSEMPET2) or for post-therapeutic PET evaluation
(OSEMPET1/PSFallpass-PET2) and to the use of PSFEANM recon-
struction for both pre- and post-therapeutic PET evaluation
(PSFEANM-PET1/PSFEANM-PET2). Kappa values were reported
using the benchmarks of Landis and Koch [32] (0.81–1
almost perfect agreement, 0.61–0.8 substantial agreement,
0.41–0.6 moderate agreement and 0.21–0.4 fair agreement).
For the kappa estimates, 95 % confidence intervals were
calculated using bootstrapping. Graphs and analyses were




As shown in Fig. 1, the OSEM 3-D reconstruction algorithm
RCs for mean and maximum values fulfilled the EANM
recommendations for both the 160-s and the 600-s emission
scan. It is noticeable that for mean values (Fig. 1a), the
OSEM RCs of the smallest spheres were slightly below
the proposed minimum EANM specification. As expected,
RCs for mean and maximum values of the PSF reconstruc-
tion algorithm without filtering were above the maximum
EANM specifications whatever the duration of the emission
scans, especially for the smallest hot spheres. When consid-
ering maximum values (Fig. 1b), with the exception of the
10-mm sphere, PSFallpass RCs were even greater than 1.0.
This can be explained by the fact that PSF modelling
results in overshoot along the edge. This artefact (the
so-called Gibbs artefact [21, 33, 34]) was visible for the
largest sphere for PSFallpass reconstruction and was par-
tially corrected for by applying the Gaussian filters.
When using shorter acquisition times, there were higher
noise levels, which in combination with the Gibbs arte-
fact led to less accurate (overestimated) measurements,
especially for the maximum pixel value. The application
of Gaussian filters with an increasing kernel during PSF
reconstruction allowed for RCs to be more consistent
with the EANM recommendations. When calculating
the RMSE, the kernel size that minimized the error
compared to EANM expected values was the kernel of
7 mm (supplementary material). This kernel size of
7 mm was then selected as the optimal filter for PSF
reconstruction (PSFEANM).
An evaluation of the potential impact of image noise on the
accuracy of our method was performed in a second experi-
ment by scanning the phantom for 1 min 40 s, 2 min 40 s and
3 min 40 s. As expected, the RC values for PSFallpass recon-
struction were higher for the shortest acquisition, due to noise
in the reconstructed images (supplementary material: Fig. 1).
However, calculation of the RMSE showed that our strategy
performed well even when image noise was higher (supple-
mentary material: Table 4).
Clinical data
Validation of the PSFEANM reconstruction to overcome
reconstruction-dependent variability
A total of 52 consecutive patients with NSCLCwere included,
for whom clinical data are summarized in Table 1. Among
these patients, 36 were referred for initial staging of NSCLC
and 16 for restaging of NSCLC recurrence.
Overall, 195 ROIs were drawn over 64 (32.8 %) primary
tumour lesions, 91 (46.7 %) mediastinal and hilar nodes
considered to have pathologically increased uptake and 40
(20.5 %) visceral and bone metastatic lesions. The mean
(SD) number of lesions per patient, all types combined, was
3.8 (3.6). Among the 91 analysed nodes, 45 (49.4 %) had a
short axis less than 1 cm [mean (SD) short axis, 0.80 (0.13)],
whereas 46 (50.6 %) had a short axis 1 cm or greater [mean
(SD) short axis, 1.46 (0.43)]. The mean SUVmean (SD) for
OSEM, PSFEANM and PSF reconstruction were 4.70 (3.43),
4.77 (3.46) and 6.24 (4.30), respectively. The mean SUVmax
(SD) for OSEM, PSFEANM and PSF reconstruction were
6.60 (4.95), 6.71 (4.97) and 9.52 (6.85), respectively.
Linear regression and Bland-Altman analysis are shown in
Fig. 2. As expected, a good correlation was found between
quantitative values extracted from the PSF and OSEM re-
constructions, with an r2 greater than 0.90 for both SUVmax
and SUVmean values. As shown in the Bland-Altman anal-
ysis, PSF reconstruction increased SUVmax and SUVmean by
48 and 37 %, respectively. An even better correlation was
found between PSFEANM and OSEM reconstruction with r
2
equal to 1.0 for SUVmax and close to 1.0 for SUVmean (0.
99). Bland-Altman analysis demonstrated that the mean
ratios between PSFEANM and OSEM quantitative values
Fig. 3 Impact of the size of the lesion (a), the BMI (b), the location of
the lesion (c), tumour homogeneity (d) and emission scan duration (e)
on the ratio between PSFEANM PET and OSEM PET quantitative
values (left panels SUVmax, right panels SUVmean). Note that 30
lesions were not measurable and are therefore not included in the
“per size” analysis (a)
b
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were 1.03 and 1.02 for SUVmax and SUVmean, respectively,
with very narrow 95 % limits of confidence in both cases.
Amongst the 195 analysed lesions, Bland-Altman plots
identified 8 outliers for the SUVmax values for which the
ratios of SUVmax PSFEANM and SUVmax OSEM were all
above the upper limit of the confidence interval. These out-
liers corresponded to one tumour, five nodes (four medias-
tinal nodes and one hilar node) and two bone metastases.
For the SUVmean values, Bland-Altman plots identified 14
outliers of which 9 had a ratio below the lower limit of the
confidence interval (2 tumours, 2 mediastinal nodes, 2 hilar
nodes, 2 bone metastases and 1 lung metastasis) and 5 above
the upper limit of the confidence interval (1 tumour, 1 hilar
node and 3 bone metastases).
As shown in Fig. 3, the ratios between PSFEANM and
OSEM quantitative values (SUVmax and SUVmean) were not
different according to the size of the lesion. The mean ratio
(SD) for SUVmax values and SUVmean values (SD) ranged
from 1.01 (0.04) (4th quartile) to 1.04 (0.05) (3rd quartile)
and from 1.01 (0.07) (1st quartile) to 1.03 (0.06) (3rd
quartile), respectively. Similarly, there was no significant
difference according to the BMI, the location of the lesion
or the type of lesion (homogeneous versus heterogeneous).
When analysing the ratios between PSFEANM and OSEM
quantitative values for SUVmax values according to BMI,
there was a trend towards higher ratios (p=0.051) in obese
patients.
An example of OSEM, PSFallpass and PSFEANM recon-
structions is shown in Fig. 4.
The use of PSFEANM quantitative values for therapy
monitoring
Among the series of 52 consecutive patients, 10 patients
underwent both a pre- and post-therapy PET evaluation with
an average time between the first and the second PET scan
of 72.6±34.6 days (Table 2).
Overall, 84 lesions were evaluated post-treatment: 12 (14.
3 %) primary tumour lesions, 41 (48.8 %) mediastinal and hilar
nodes and 31 (36.9 %) visceral and bone metastatic lesions.
When OSEM reconstruction was used for interpreting both pre-
and post-therapeutic PET examinations (OSEMPET1/
OSEMPET2), 37 lesions were considered to have had a CMR,
28 a PMR, 13 were stable and 6 had progressed. These results
were then compared to several scenarios (Fig. 5, Table 3) when
using PSFEANM, OSEM or PSFallpass for either the pre- or post-
therapeutic PET examination or both. OSEMPET1/OSEMPET2
was regarded as the standard of reference. All lesions considered,
there was almost perfect agreement between OSEMPET1/
OSEMPET2 and OSEMPET1/PSFEANM-PET2, PSFEANM-
PET1/OSEMPET2 or PSFEANM-PET1/PSFEANM-PET2 with kappa
values higher than 0.90. In addition, the associated 95 % confi-
dence intervals virtually matched the almost perfect range of
kappa values. When analysing tumours, nodes or visceral and
bone metastases separately, the strength of agreement was also
considered to be very good. There were four cases (4.8 %) of
disagreement (two nodes and two metastatic lesions) in which
OSEMPET1/PSFEANM-PET2 diagnosed stable disease, whereas
OSEMPET1/OSEMPET2 identified partial response. When
PSFEANM-PET1/OSEMPET2 was used, there was only one dis-
agreement (1.2 %) that occurred in a node, coming to a conclu-
sion of stable disease, whereas OSEMPET1/OSEMPET2 identified
partial response. With PSFEANM-PET1/PSFEANM-PET2, there were
two cases of disagreement that occurred in nodes, coming to a
conclusion of stable disease, whereas OSEMPET1/OSEMPET2
identified partial response.
Importantly, when PSFallpass reconstruction was used either
for the pre- or post-therapeutic examination (OSEMPET1/
PSFallpass-PET2 or PSFallpass-PET1/OSEMPET2), there was consider-
ably less agreement. With OSEMPET1/PSFallpass-PET2, there were
Fig. 4 Representative coronal
slices for OSEM, PSFallpass and
PSFEANM reconstructions in a
patient with a lung tumour in
the left upper lobe, bilateral
nodal involvement (a) and
distant metastases (lung, bone
and liver) (b). Images have
been scaled on the same
maximum value. Note the
improvement in activity
recovery visible in a small lung
metastasis on the PSFallpass
image (arrow)
992 Eur J Nucl Med Mol Imaging (2013) 40:985–996
overall 23 cases (27.4 %) of disagreement (4 tumours, 13 nodes
and 6 metastatic lesions) in which OSEMPET1/PSFallpass-PET2
underestimated the therapeutic response when compared to
OSEMPET1/OSEMPET2. With PSFallpass-PET1/OSEMPET2, there
were 11 cases (13.1 %) of disagreement including 9 cases (6
nodes and 3 metastatic lesions) where a conclusion of partial
response was reached, whereas OSEMPET1/OSEMPET2 diag-
nosed stable disease. The remaining two cases corresponded to
tumours: one for which PSFallpass-PET1/OSEMPET2 reached a
conclusion of stable disease, whereas OSEMPET1/OSEMPET2
identified partial response, and one for which PSFallpass-
PET1/OSEMPET2 diagnosed progression, whereas OSEMPET1/
OSEMPET2 identified stable disease.
Discussion
18F-FDG PET has an increasing role in oncology for
staging, restaging and therapy monitoring of chemother-
apy and molecularly targeted therapies and is being in-
creasingly implemented in clinical trials, especially for
the early assessment of antineoplastic treatments. This
prospective study in NSCLC patients validates a strategy
allowing the use of quantitative values within the framework
of multicentre trials, which is based on the production of
protocol-specific images, in addition to images optimized for
diagnostic purpose.
Standardized quantification of PET data in multicentre
trials as described in the EANM guidelines allows for reli-
able and reproducible treatment response assessment.
However, standardization remains a major challenge as
new, more sensitive PET systems and reconstruction algo-
rithms are continuously being developed and introduced
into clinical practice [20, 23, 35]. In the present study, we
validated a strategy in which the recently introduced PSF
reconstruction algorithm can be used not only for visual but
also for quantitative analysis of PET imaging, whilst adher-
ing to the EANM guidelines. Our results demonstrate, by
mimicking a situation in which a patient would undergo the
pre- and post-therapy PET scans on different generation PET
systems, that it is possible to minimize reconstruction-
dependent variability. Hence, Bland-Altman analysis (Fig. 2)
showed that after having applied an adequate filter (PSFEANM)
the upper limit of the confidence intervals was 12 %, a value
well below the 25 and 30 % cut-off values recommended by
EORTC [30] and PERCIST [36], respectively, to discriminate
between responders and non-responders when using 18F-FDG
PET for therapy monitoring. Importantly, we confirmed this
finding in a subset of ten patients who underwent two PET
examinations for response assessment (Table 2). In these
Table 2 Characteristics of pa-
tients who underwent post-ther-
apy evaluation
F female, M male
Patient Sex Age Number of lesions Treatment Delay between PET1
and PET2 (days)
PET1 PET2
1 F 79 7 3 Gefitinib 168
2 M 60 8 1 Cisplatin-pemetrexed 70
3 M 67 7 8 Cisplatin-vinorelbine 83
4 M 58 8 7 Carboplatin-pemetrexed 42
5 M 59 15 6 Cisplatin-pemetrexed-bevacizumab 56
6 M 80 1 2 Carboplatin-paclitaxel 54
7 M 65 11 8 Cisplatin-pemetrexed 52
8 M 53 2 2 Cisplatin-vinorelbine 105
9 M 54 6 6 Cisplatin-pemetrexed 49
10 M 65 13 5 Cisplatin-gemcitabine 118
Fig. 5 Flow chart for the





either pre- or post-treatment as
compared to the exclusive use
of OSEM reconstruction
(current standard)
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patients, an excellent agreement was found (kappa values 0.95
and 0.99) in the post-treatment classification of 84 lesions
according to EORTC criteria when comparing PSFEANM either
pre- or post-therapy to OSEM as the current standard, and no
major discordance occurred. However, when the PSFallpass data
were used either pre- or post-therapy compared to OSEM, we
saw considerably less agreement. Due to system updates on
existing PET systems or the purchase of a new PET machine,
OSEMPET1/PSFallpass-PET2 is the situation most likely to occur.
In this situation, our data showed discordance in 27.4 % of
lesions.
The proposed strategy can be useful in the case of pa-
tients undergoing pre- and post-treatment scans on different
PET systems, for example in centres running two or more
PET systems or updating their equipment during the course
of a trial. Of course, it would be preferable to scan the
patient repeatedly on the same machine, but in practice this
is often not possible. Moreover, in the setting of multicentre
trials there are two other situations in which standardization
of PET quantitative values is required: when pooling SUV
from different PET/CT systems for diagnostic purposes (i.e.
to determine a specific diagnostic threshold value for a
given disease) [8, 9] or as a prognostic tool (i.e. to search
for the impact of tumour tracer uptake on disease-free and
overall survival) [10, 11].
Regarding practical issues related to the proposed method-
ology, determination of the appropriate filter per PET system
is required by performing the phantom studies and reconstruc-
tions with a Gaussian filter with increasing kernel as described
in the “Materials and methods” section. Once the optimal filter
meeting the EANM expected values is determined, the filtered
PET data can be used for both local and multicentre quantita-
tive PET analysis. This method can be readily applied on any
PET scanner equipped with PSF; the purchase of additional
software is not necessary. However, this method does not
obviate the need to generate a second data set which is time
consuming. Of course, the choice to use either an OSEM
reconstruction or a filtered PSF algorithm for the standardized
quantitative analysis remains a choice of local nuclear medi-
cine physicians, physicists and researchers, just like the choice
to systematically reconstruct non-attenuation-corrected im-
ages or only when clinically needed. Choosing PSFEANM
could be the preferred solution, as PSF reconstruction is meant
to progressively replace former generation PET systems.
As pointed out by Boellaard [24], patients are frequently
included in clinical trials after the first PET examination has
been performed. This emphasizes the need to standardize
the PET procedure from the very beginning of patient care.
However, PET acquisition and reconstruction parameters are
not the only source of variability that has to be taken into
account. Other technical and biological factors also affect
SUV measurements. These factors have been discussed
extensively elsewhere [12, 24, 37]. In the present study,
one technical factor, the reconstruction protocol, has been
analysed. To minimize the influence of the other technical
and biological factors affecting SUV measurements in this
study, all PET examinations were performed according to
the EANM guidelines. Of note, the injected activity per
kilogram and the delay between injection and acquisition
met the EANM requirements.
The potential impact of image noise on the accuracy of
our method was evaluated in phantom studies by varying the
acquisition time. Calculation of the RMSE values between
PSFEANM and EANM expected values showed that our
strategy performed well when image noise was higher, the
values being similar for the shortest and longest acquisition
times. This was confirmed by clinical data showing no
difference in PSFEANM/OSEM ratios for the 2 min 40 s
and 3 min 40 s per bed position acquisition times (Fig. 3e).
We found no confounding factors (lesion size and loca-
tion, tumour heterogeneity, patient BMI) affecting the accu-
racy of our method. However, we noticed a trend towards
higher PSFEANM/OSEM ratios in overweight and obese
patients for SUVmax (Fig. 3b). This may be due to the fact
that noise in PET images is higher in obese patients and
SUVmax is more affected by noise than SUVmean. The
Table 3 Impact of PSFEANM on response evaluation
















All lesions 0.95 (0.91–1.00) 0.99 (0.96–1.00) 0.98 (0.94–1.00) 0.75 (0.67–0.83) 0.86 (0.78–0.94)
Tumours 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 0.59 (0.28–0.90) 0.76 (0.52–0.99)
Nodes 0.94 (0.86–1.00) 0.97 (0.91–1.00) 0.94 (0.86–1.00) 0.69 (0.59–0.78) 0.80 (0.67–0.92)
Metastasis 0.95 (0.88–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 0.83 (0.70–0.96) 0.92 (0.83–1.00)
Linear-weighted kappa values for all lesions as well as for different lesion types, when using PSFEANM or PSFallpass reconstructions for response
monitoring (EORTC criteria) either pre- or post-treatment as compared to the exclusive use of OSEM reconstruction (current standard)
CI confidence interval
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observed difference was minimal and did not affect the
EORTC classification based on SUVmax (Table 3). The use
of SUVpeak, which is defined as the mean value within an
ROI centred on the area with the highest uptake, has been
reported as a slightly more robust alternative for assessing
the most metabolically active part of a tumour [19].
However, SUVpeak is highly sensitive to the ROIpeak defini-
tion (i.e. shape, size and location) [38], was shown to have
similar repeatability as compared to SUVmax [39] and does
not necessarily perform better than SUVmax for therapy
assessment [40]. In the present study, a wide range of tumour
intensities was studied and no systematic error was depicted
by Bland-Altman analysis (i.e. the strategy performs equally
for lesions with low 18F-FDG avidity and for those with very
intense 18F-FDG uptake). This finding, taken together with the
lack of confounding factors affecting our strategy, suggests
that it could be applicable in other solid tumours.
Conclusion
The generation of protocol-specific images with NEMA NU-2
phantom-based filtering to meet EANM quantitative harmo-
nizing standards, in addition to images optimized for diagnos-
tic purposes, reduces reconstruction-dependent variation in
SUVs. This can be of use in multicentre trials, when using
SUV for therapy monitoring, or as a diagnostic or prognostic
tool. As no confounding factors (lesion size and location,
tumour heterogeneity, patient BMI, image noise) affecting the
accuracy of our method were found, this strategy validated in
NSCLC patients could be extrapolated to other solid tumours.
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